Save Product
Product Details
- ProductSizeAmountActiveMax® Human BCMA μBeads, premium grade (for cells)2.5 mg2.5×10⁷ beadsActiveMax® Human BCMA μBeads, premium grade (for cells)10 mg (2.5 mg×4)1.0×10⁸ beads
Product Description
ActiveMax® Human BCMA μBeads, premium grade (for cells) are uniform, superparamagnetic beads of 5.5 µm in diameter immobilized with Human BCMA protein expressed from human 293 cells (HEK293) and contains AA Met 1 - Ala 54 (Accession # Q02223-1).
ActiveMax® Human BCMA μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.Application
ActiveMax® Human BCMA μBeads, premium grade (for cells) are designed to stimulate in vitro BCMA-specific CAR-T cells or UCAR-T cells, similar to the tumor cell lines that express human BCMA antigen. It can be used as follows:
Evaluating the characteristics of CAR-T cells or UCAR-T cells.
In vitro expansion of BCMA-specific CAR-T cells or UCAR-T cells.
In vitro enrichment of BCMA-specific CAR-T cells or UCAR-T cells.Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
This product is stable in storage under the following conditions: -20˚C for 12 months in lyophilized state. -70°C for 3 months under sterile conditions after reconstitution.
Please avoid repeated freeze-thaw cycles after reconstitution. Immediate use after reconstitution is highly recommended.
Endotoxin
Less than 0.002 EU per μg by the LAL method / rFC method.
Important Note
This product is for research use only and not intended for therapeutic or in vivo diagnostic use.
Formulation
Please contact us for detailed information.
Contact us for customized product form or formulation.
ACRO Quality Management System
Customers Also Viewed
Performance Data
FACS Data
Assay of human BCMA protein on the μBeads surface by Flow cytomtry. The human BCMA conjugated on the μBeads (Cat. No. MBS-C004) surface were fluorescently stained using PE labeled anti-human BCMA antibody and analyzed by flow cytometry.
Protocol
Batch Consistency
Add 100ul of 1:40 PE anti-human BCMA Antibody dilution (2.5ul stock solution in 100ul FACS buffer) into 5e5 of ActiveMax® human BCMA μBeads, premium grade (for cells) (Cat. No. MBS-C004), negative control beads (ActiveMax® Streptavidin μBeads, premium grade (for cells) (Cat. No. MBS-C009)) as well. PE signals was used to evaluate BCMA beads binding activity.
Stability
Add 100ul of 1:40 PE anti-human BCMA Antibody dilution (5ul stock solution in 100ul FACS buffer) into 5e5 of ActiveMax® human BCMA μBeads, premium grade (for cells) (Cat. No. MBS-C004), Negative control (ActiveMax® Streptavidin μBeads, premium grade (for cells) (Cat. No. MBS-C009)) as well. PE signals was used to evaluate BCMA beads binding activity.
Stimulate BCMA CAR-T Cells -Cytokines
ActiveMax® Human BCMA μBeads, premium grade (for cells) (Cat.No.MBS-C004) can activate BCMA-specific CAR-T cells by detecting the secretion of IFN- γ in vitro.
BCMA CAR-T cells were stimulated with ActiveMax® Human BCMA μBeads (Cat. No. MBS-C004) for 24 h, and cell-free supernatants were harvested for evaluating IFN-γ、TNF-α、IL-4 secretion by flow cytomtry. The results showed that BCMA CAR-T cells released significantly larger amounts of IFN-γ、TNF-α、IL-4 into the supernatants in response to BCMA μBeads.
Stimulate BCMA CAR-T Cells -Cytotoxic Molecules
BCMA CAR-T cells were stimulated with ActiveMax® Human BCMA μBeads (Cat. No. MBS-C004) for 24h, and cell-free supernatants were harvested for evaluating Granzyme B secretion by ELISA. The results showed that BCMA CAR-T cells released significantly larger amounts of Granzyme B into the supernatants in response to BCMA μBeads.
Stimulate BCMA CAR-T Cells -Activation Marker
BCMA CAR-T cells were stimulated with ActiveMax® Human BCMA μBeads (MBS-C004) for 24h. After demagnetization of the beads, the cells were collected and CD25, CD69, and CD137 were detected by FACS. The results indicated that BCMA CAR-T cells responded to BCMA μBeads, and the expressions of the three markers increased.
Stimulate BCMA CAR-T Cells -Exhaustion Marker
BCMA CAR-T cells were stimulated with ActiveMax® Human BCMA μBeads (MBS-C004) for 24h. After demagnetization of the beads, the cells were collected and LAG3, PD-1 were detected by FACS. The results indicated that BCMA CAR-T cells responded to BCMA μBeads, and the expressions of the two markers increased.
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
B-cell maturation protein
- Category：
- Approved Drugs：
7 Details
- Drugs in Clinical Trials：
117 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing